These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21386934)

  • 61. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
    Bavishi C; Bangalore S; Messerli FH
    Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Olmesartan medoxomil: a review of its use in the management of hypertension.
    Scott LJ; McCormack PL
    Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
    Imaizumi S; Miura S; Yahiro E; Uehara Y; Komuro I; Saku K
    Curr Pharm Des; 2013; 19(17):3002-8. PubMed ID: 23176212
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
    Volpe M
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New standards in hypertension and cardiovascular risk management: focus on telmisartan.
    Galzerano D; Capogrosso C; Di Michele S; Galzerano A; Paparello P; Lama D; Gaudio C
    Vasc Health Risk Manag; 2010 Mar; 6():113-33. PubMed ID: 20448797
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
    Mason RP
    Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM
    Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
    ARB Trialists Collaboration
    J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Renin-angiotensin system blockade and cardiovascular and renal protection.
    Hoogwerf BJ
    Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of Angiotensin receptor blockers in cardiovascular disease.
    Maggioni AP
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):295-308. PubMed ID: 16915347
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of the renin-angiotensin system and the prevention of stroke.
    Schrader J; Kulschewski A; Dendorfer A
    Am J Cardiovasc Drugs; 2007; 7(1):25-37. PubMed ID: 17355164
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R
    Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sympatho-inhibitory properties of various AT1 receptor antagonists.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.
    Meredith PA
    Am J Cardiovasc Drugs; 2005; 5(3):171-83. PubMed ID: 15901205
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
    Minatoguchi S; Aoyama T; Kawai N; Iwasa M; Oda M; Kida K; Kojima S; Goto N; Goto M; Sugishita F; Takai K; Tanaka R; Hiei K; Minagawa T; Yamamoto N; Watanabe I; Yasue T; Kobayashi H
    Blood Press; 2013 Sep; 22 Suppl 1():29-37. PubMed ID: 23330658
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
    Chrysant SG; Chrysant GS
    J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.